188 related articles for article (PubMed ID: 2894481)
1. Tumor regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995.
Wiedenmann B; Räth U; Rädsch R; Becker F; Kommerell B
Klin Wochenschr; 1988 Jan; 66(2):75-7. PubMed ID: 2894481
[TBL] [Abstract][Full Text] [Related]
2. The use of a long-acting somatostatin analogue in the treatment of advanced endocrine malignancies with gastrointestinal symptoms.
Ahlman H; Tisell LE
Scand J Gastroenterol; 1987 Oct; 22(8):938-42. PubMed ID: 2891186
[TBL] [Abstract][Full Text] [Related]
3. Successful symptomatic treatment of malignant carcinoid syndrome with the somatostatin analogue SMS 201-995.
van Houten AA; Nortier JW; Vendrik CP
Neth J Med; 1988 Apr; 32(3-4):194-8. PubMed ID: 2896307
[No Abstract] [Full Text] [Related]
4. Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy.
Boehme MW; Schmidt-Gayk H; Bihl H; Eisenhut M; Herfarth CH; Kommere B; Raeth U
Hepatogastroenterology; 1995; 42(6):1053-61. PubMed ID: 8847018
[TBL] [Abstract][Full Text] [Related]
5. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
6. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E; Deshpande HA; Stein SM
Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
[TBL] [Abstract][Full Text] [Related]
7. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin analogue phase I trials in neuroendocrine neoplasms.
Anthony L; Johnson D; Hande K; Shaff M; Winn S; Krozely M; Oates J
Acta Oncol; 1993; 32(2):217-23. PubMed ID: 7686764
[TBL] [Abstract][Full Text] [Related]
9. The tumour vanishes.
Todd JF; Meeran K
Clin Endocrinol (Oxf); 2000 Dec; 53(6):663-4. PubMed ID: 11155085
[No Abstract] [Full Text] [Related]
10. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
[TBL] [Abstract][Full Text] [Related]
11. Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy.
Kvols LK
Am J Med; 1986 Dec; 81(6B):49-55. PubMed ID: 2432781
[TBL] [Abstract][Full Text] [Related]
12. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.
Oberg K; Norheim I; Theodorsson E
Acta Oncol; 1991; 30(4):503-7. PubMed ID: 1854508
[TBL] [Abstract][Full Text] [Related]
13. Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours.
Rohaizak M; Farndon JR
ANZ J Surg; 2002 Sep; 72(9):635-8. PubMed ID: 12269913
[TBL] [Abstract][Full Text] [Related]
14. Carcinoid of the pancreas.
Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
[TBL] [Abstract][Full Text] [Related]
15. Use of a somatostatin analogue in association with surgery and hepatic arterial embolisation in the treatment of the carcinoid syndrome.
Ahlman H; Ahlund L; Dahlström A; Nilsson O; Skolnik G; Tisell LE; Tylén U
Br J Cancer; 1987 Dec; 56(6):840-2. PubMed ID: 2893640
[No Abstract] [Full Text] [Related]
16. [Isotopic scan with somatostatin receptors in a case of recurrent carcinoid tumor. Relevance of tomographic detection].
Bernà Roqueta L; Martín Marimón JC; Martín Martínez J
Rev Esp Med Nucl; 2002 Apr; 21(2):123-4. PubMed ID: 11879622
[No Abstract] [Full Text] [Related]
17. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin, anaesthesia, and the carcinoid syndrome. Peri-operative administration of a somatostatin analogue to suppress carcinoid tumour activity.
Roy RC; Carter RF; Wright PD
Anaesthesia; 1987 Jun; 42(6):627-32. PubMed ID: 2887127
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes.
Vinik AI; Tsai ST; Moattari AR; Cheung P; Eckhauser FE; Cho K
Am J Med; 1986 Dec; 81(6B):23-40. PubMed ID: 2879447
[TBL] [Abstract][Full Text] [Related]
20. Carcinoid tumor regression with high-dose octreotide acetate: a patient report.
Lokich J
Am J Clin Oncol; 1998 Jun; 21(3):246-7. PubMed ID: 9626790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]